{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:45:46Z","timestamp":1789152346276,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00428-025-04196-1","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T03:43:54Z","timestamp":1753328634000},"page":"865-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunohistochemistry scoring for human epidermal growth factor receptor 2 can be used to predict pathological response to cisplatin-based neoadjuvant chemotherapy in a subset of immunohistochemically subtyped muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"488","author":[{"given":"Manduwa","family":"Saka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"4196_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC Van Hoogstraten","year":"2023","unstructured":"Van Hoogstraten LMC, Vrieling A, van der Heijden AG et al (2023) Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol 20:287\u2013304. https:\/\/doi.org\/10.1038\/s41571-023-00744-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4196_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4196_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.humpath.2022.08.006","volume":"136","author":"SK Mohanty","year":"2023","unstructured":"Mohanty SK, Lobo A, Cheng L (2023) The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges. Hum Pathol 136:123\u2013143. https:\/\/doi.org\/10.1016\/j.humpath.2022.08.006","journal-title":"Hum Pathol"},{"key":"4196_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/s0140-6736(09)60491-8","volume":"374","author":"DS Kaufman","year":"2009","unstructured":"Kaufman DS, Shipley WU, Feldman AS (2009) Bladder cancer. Lancet Lond Engl 374:239\u2013249. https:\/\/doi.org\/10.1016\/s0140-6736(09)60491-8","journal-title":"Lancet Lond Engl"},{"key":"4196_CR5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M et al (2024) NCCN Guidelines\u00ae Insights: bladder cancer, Version 3.2024: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 22:216\u2013225. https:\/\/doi.org\/10.6004\/jnccn.2024.0024","journal-title":"J Natl Compr Canc Netw"},{"key":"4196_CR6","doi-asserted-by":"publisher","unstructured":"Advanced Bladder Cancer Overview Collaboration (2004) Neoadjuvant chemotherapy for invasive bladder cancer. Cochrane Database Syst Rev CD005246. https:\/\/doi.org\/10.1002\/14651858.cd005246","DOI":"10.1002\/14651858.cd005246"},{"key":"4196_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/nejmoa022148","volume":"349","author":"HB Grossman","year":"2003","unstructured":"Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859\u2013866. https:\/\/doi.org\/10.1056\/nejmoa022148","journal-title":"N Engl J Med"},{"key":"4196_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","volume":"67","author":"H Zargar","year":"2015","unstructured":"Zargar H, Espiritu PN, Fairey AS et al (2015) Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 67:241\u2013249. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.007","journal-title":"Eur Urol"},{"key":"4196_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","volume":"61","author":"R Rosenblatt","year":"2012","unstructured":"Rosenblatt R, Sherif A, Rintala E et al (2012) Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol 61:1229\u20131238. https:\/\/doi.org\/10.1016\/j.eururo.2011.12.010","journal-title":"Eur Urol"},{"key":"4196_CR10","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","volume":"65","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Cabiddu M et al (2014) Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis. Eur Urol 65:350\u2013357. https:\/\/doi.org\/10.1016\/j.eururo.2013.06.049","journal-title":"Eur Urol"},{"key":"4196_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A et al (2021) Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG\/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur Urol 79:214\u2013221. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.024","journal-title":"Eur Urol"},{"key":"4196_CR12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun A, de Reyni\u00e8s A, Allory Y et al (2020) A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol 77:420\u2013433. https:\/\/doi.org\/10.1016\/j.eururo.2019.09.006","journal-title":"Eur Urol"},{"key":"4196_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00428-022-03361-0","volume":"481","author":"FJ Queipo","year":"2022","unstructured":"Queipo FJ, Unamunzaga GM, Negro BF et al (2022) Immunohistochemistry subtyping of urothelial carcinoma is feasible in the daily practice. Virchows Arch Int J Pathol 481:191\u2013200. https:\/\/doi.org\/10.1007\/s00428-022-03361-0","journal-title":"Virchows Arch Int J Pathol"},{"key":"4196_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/path.5318","volume":"249","author":"C Bernardo","year":"2019","unstructured":"Bernardo C, Eriksson P, Marzouka NAD et al (2019) Molecular pathology of the luminal class of urothelial tumors. J Pathol 249:308\u2013318. https:\/\/doi.org\/10.1002\/path.5318","journal-title":"J Pathol"},{"key":"4196_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.eururo.2021.10.035","volume":"81","author":"G Sj\u00f6dahl","year":"2022","unstructured":"Sj\u00f6dahl G, Abrahamsson J, Holmsten K et al (2022) Different responses to neoadjuvant chemotherapy in urothelial carcinoma molecular subtypes. Eur Urol 81:523\u2013532. https:\/\/doi.org\/10.1016\/j.eururo.2021.10.035","journal-title":"Eur Urol"},{"key":"4196_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.70017","volume":"11","author":"C Olah","year":"2025","unstructured":"Olah C, Shmorhun O, Klamminger GG et al (2025) Immunohistochemistry-based molecular subtypes of urothelial carcinoma derive different survival benefit from platinum chemotherapy. J Pathol Clin Res 11:e70017. https:\/\/doi.org\/10.1002\/2056-4538.70017","journal-title":"J Pathol Clin Res"},{"issue":"4","key":"4196_CR17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/ijms20040793","volume":"20","author":"J Tse","year":"2019","unstructured":"Tse J, Ghandour R, Singla N et al (2019) Molecular predictors of complete response following neoadjuvant chemotherapy in urothelial carcinoma of the bladder and upper tracts. Int J Mol Sci 20(4):793. https:\/\/doi.org\/10.3390\/ijms20040793","journal-title":"Int J Mol Sci"},{"key":"4196_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","volume":"69","author":"FH Groenendijk","year":"2016","unstructured":"Groenendijk FH, De Jong J, Fransen van de Putte EE et al (2016) ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 69:384\u2013388. https:\/\/doi.org\/10.1016\/j.eururo.2015.01.014","journal-title":"Eur Urol"},{"key":"4196_CR19","doi-asserted-by":"publisher","first-page":"42713","DOI":"10.1038\/srep42713","volume":"7","author":"B Kiss","year":"2017","unstructured":"Kiss B, Wyatt AW, Douglas J et al (2017) Her2 alterations in muscle-invasive bladder cancer: patient selection beyond protein expression for targeted therapy. Sci Rep 7:42713. https:\/\/doi.org\/10.1038\/srep42713","journal-title":"Sci Rep"},{"issue":"3","key":"4196_CR20","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/PAS.0000000000000142","volume":"38","author":"A Fleishmann","year":"2014","unstructured":"Fleishmann A, Thalmann GN, Perren A et al (2014) Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival. Am J Surg Pathol 38(3):325\u2013332. https:\/\/doi.org\/10.1097\/PAS.0000000000000142","journal-title":"Am J Surg Pathol"},{"key":"4196_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","volume":"12","author":"V Dadhania","year":"2016","unstructured":"Dadhania V, Zhang M, Zhang L et al (2016) Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use. EBioMedicine 12:105\u2013117. https:\/\/doi.org\/10.1016\/j.ebiom.2016.08.036","journal-title":"EBioMedicine"},{"key":"4196_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5858\/arpa.2017-0286-cp","volume":"142","author":"JS Lewis","year":"2018","unstructured":"Lewis JS, Beadle B, Bishop JA et al (2018) Human papillomavirus testing in head and neck carcinomas: guideline from the college of american pathologists. Arch Pathol Lab Med 142:559\u2013597. https:\/\/doi.org\/10.5858\/arpa.2017-0286-cp","journal-title":"Arch Pathol Lab Med"},{"key":"4196_CR23","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/modpathol.2011.85","volume":"24","author":"A Yemelyanova","year":"2011","unstructured":"Yemelyanova A, Vang R, Kshirsagar M et al (2011) Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol 24:1248\u20131253. https:\/\/doi.org\/10.1038\/modpathol.2011.85","journal-title":"Mod Pathol"},{"key":"4196_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s004280050056","volume":"430","author":"NH Chow","year":"1997","unstructured":"Chow NH, Liu HS, Yang HB et al (1997) Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. Virchows Arch 430:461\u2013466. https:\/\/doi.org\/10.1007\/s004280050056","journal-title":"Virchows Arch"},{"key":"4196_CR25","doi-asserted-by":"publisher","unstructured":"Wolff AC, Somerfield MR, Dowsett M, et al (2023) Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update. J Clin Oncol Off J Am Soc Clin Oncol JCO2202864. https:\/\/doi.org\/10.1200\/jco.22.02864","DOI":"10.1200\/jco.22.02864"},{"key":"4196_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13000-024-01455-8","volume":"19","author":"V Peg","year":"2024","unstructured":"Peg V, Moline T, Roig M et al (2024) Clinical application of the HM-1000 image processing for HER2 fluorescence in situ hybridization signal quantification in breast cancer. Diagn Pathol 19:32. https:\/\/doi.org\/10.1186\/s13000-024-01455-8","journal-title":"Diagn Pathol"},{"key":"4196_CR27","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.5858\/arpa.2013-0953-sa","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond MEH, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol 31:3997\u20134013. https:\/\/doi.org\/10.5858\/arpa.2013-0953-sa","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4196_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00428-015-1729-4","volume":"466","author":"J Tschui","year":"2015","unstructured":"Tschui J, Vassella E, Bandi N et al (2015) Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch Int J Pathol 466:703\u2013710. https:\/\/doi.org\/10.1007\/s00428-015-1729-4","journal-title":"Virchows Arch Int J Pathol"},{"key":"4196_CR29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"4196_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/jpm11060473","volume":"11","author":"H J\u00fctte","year":"2021","unstructured":"J\u00fctte H, Reike M, Wirtz RM et al (2021) KRT20, KRT5, ESR1 and ERBB2 expression can predict pathologic outcome in patients undergoing neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer. J Pers Med 11:473. https:\/\/doi.org\/10.3390\/jpm11060473","journal-title":"J Pers Med"},{"key":"4196_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ebiom.2018.06.011","volume":"35","author":"Z Yang","year":"2018","unstructured":"Yang Z, Zhang R, Ge Y et al (2018) Somatic FGFR3 mutations distinguish a subgroup of muscle-invasive bladder cancers with response to neoadjuvant chemotherapy. EBioMedicine 35:198\u2013203. https:\/\/doi.org\/10.1016\/j.ebiom.2018.06.011","journal-title":"EBioMedicine"},{"key":"4196_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/path.4886","volume":"242","author":"G Sj\u00f6dahl","year":"2017","unstructured":"Sj\u00f6dahl G, Eriksson P, Liedberg F et al (2017) Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification. J Pathol 242:113\u2013125. https:\/\/doi.org\/10.1002\/path.4886","journal-title":"J Pathol"},{"key":"4196_CR33","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.3390\/ijms24043720","volume":"24","author":"F Sanguedolce","year":"2023","unstructured":"Sanguedolce F, Zanelli M, Palicelli A et al (2023) HER2 expression in bladder cancer: a focused view on its diagnostic, prognostic, and predictive Role. Int J Mol Sci 24:3720. https:\/\/doi.org\/10.3390\/ijms24043720","journal-title":"Int J Mol Sci"},{"key":"4196_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","volume":"68","author":"ER Plimack","year":"2015","unstructured":"Plimack ER, Dunbrack RL, Brennan TA et al (2015) Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 68:959\u2013967. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.009","journal-title":"Eur Urol"},{"key":"4196_CR35","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/2159-8290.cd-14-0623","volume":"4","author":"EM Van Allen","year":"2014","unstructured":"Van Allen EM, Mouw KW, Kim P et al (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4:1140\u20131153. https:\/\/doi.org\/10.1158\/2159-8290.cd-14-0623","journal-title":"Cancer Discov"},{"key":"4196_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.eururo.2024.06.018","volume":"86","author":"ER Plimack","year":"2024","unstructured":"Plimack ER, Tangen C, Plets M et al (2024) Correlative analysis of ATM, RB1, ERCC2, and FANCc mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: results from the SWOG S1314 Trial. Eur Urol 86:297\u2013300. https:\/\/doi.org\/10.1016\/j.eururo.2024.06.018","journal-title":"Eur Urol"},{"key":"4196_CR37","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","volume":"3","author":"R Bose","year":"2013","unstructured":"Bose R, Kavuri SM, Searleman AC et al (2013) Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:224\u2013237. https:\/\/doi.org\/10.1158\/2159-8290.CD-12-0349","journal-title":"Cancer Discov"},{"key":"4196_CR38","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.clgc.2013.10.002","volume":"12","author":"M Mossanen","year":"2014","unstructured":"Mossanen M, Lee F, Cheng H et al (2014) Nonresponse to neoadjuvant chemotherapy for muscle-invasive urothelial cell carcinoma of the bladder. Clin Genitourin Cancer 12:210\u2013213. https:\/\/doi.org\/10.1016\/j.clgc.2013.10.002","journal-title":"Clin Genitourin Cancer"},{"key":"4196_CR39","doi-asserted-by":"publisher","first-page":"12659","DOI":"10.3390\/ijms232012659","volume":"23","author":"V Albarr\u00e1n","year":"2022","unstructured":"Albarr\u00e1n V, Rosero DI, Chamorro J et al (2022) Her-2 targeted therapy in advanced urothelial cancer: from monoclonal antibodies to antibody-drug conjugates. Int J Mol Sci 23:12659. https:\/\/doi.org\/10.3390\/ijms232012659","journal-title":"Int J Mol Sci"},{"key":"4196_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1369\/00221554221095530","volume":"70","author":"CSC Hardy","year":"2022","unstructured":"Hardy CSC, Ghaedi H, Slotman A et al (2022) Immunohistochemical assays for bladder cancer molecular subtyping: optimizing parsimony and performance of lund taxonomy classifiers. J Histochem Cytochem Off J Histochem Soc 70:357\u2013375. https:\/\/doi.org\/10.1369\/00221554221095530","journal-title":"J Histochem Cytochem Off J Histochem Soc"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-025-04196-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-025-04196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T15:49:31Z","timestamp":1775490571000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-025-04196-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4196"],"URL":"https:\/\/doi.org\/10.1007\/s00428-025-04196-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}